Results 271 to 280 of about 138,770 (367)

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors. [PDF]

open access: yesMedicina (Kaunas)
Sucuoğlu İşleyen Z   +8 more
europepmc   +1 more source

Pandering to Persuade [PDF]

open access: yes
Navin Kartik   +2 more
core  

Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy

open access: yesCancer Medicine, Volume 14, Issue 15, August 2025.
ABSTRACT Introduction Soft tissue sarcomas are a diverse group of rare cancers, with approximately 15%–20% found in the retroperitoneum. Liposarcomas (LPS) make up approximately half of all retroperitoneal (RP) sarcomas, with most cases classified as either well‐differentiated (WD) or dedifferentiated (DD).
Steven Sun   +2 more
wiley   +1 more source

Performance of novel tau antibodies across multiple modalities for Alzheimer's disease assessment. [PDF]

open access: yesAlzheimers Dement
Trivedi P   +14 more
europepmc   +1 more source

Two-dimensional QSAR-driven virtual screening for potential therapeutics against <i>Trypanosoma cruzi</i>. [PDF]

open access: yesFront Chem
Maliyakkal N   +5 more
europepmc   +1 more source

OLOMOUCINE II, NEW EFFECTIVE CDK INHIBITOR WITH STRONG CYTOTOXIC PROPERTIES

open access: gold, 2001
René Lenobel   +4 more
openalex   +1 more source

Fucoidan From Brown Algae as a Functional Food Ingredient: A Promising Anticancer Agent

open access: yeseFood, Volume 6, Issue 4, August 2025.
Fucoidan, a bioactive polysaccharide from brown algae, inhibits receptor tyrosine kinase (RTK) activation and vascular endothelial growth factor (VEGF) signaling, suppressing the phosphoinositide 3‐kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) and RAS/RAF/mitogen‐activated protein kinase/extracellular signal‐regulated kinase ...
Muhammad Umer Khan   +7 more
wiley   +1 more source

Cyclin E and Its Associated cdk Activity Do Not Cycle during Early Embryogenesis of the Sea Urchin

open access: green, 2001
Jan L. Sumerel   +6 more
openalex   +2 more sources

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

open access: yesESC Heart Failure, Volume 12, Issue 4, Page 3062-3072, August 2025.
Abstract Aims Mineralocorticoid receptor antagonists (MRAs) are crucial in managing cardiovascular diseases, with different MRAs demonstrating varying efficacy across diverse disease contexts. This research aims to compare the cardiovascular protective effects of different MRAs across various disease conditions.
Jiao Wang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy